(RTTNews) - GH Research PLC (GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, announced ...

In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other healthcare stocks. The healthcare sector is staging a comeback so far in 2025 after two ...

In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other psychedelic stocks. In contrast to drugs like cocaine or marijuana, psychedelics are ...

Guggenheim initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target The firm’s thesis on GH is based around the belief that rapid-acting psychedelics like 5-MeO-DMT have ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other small cap stocks. On February 14, Stacey Sears, portfolio manager at Emerald Advisors ...

Fintel reports that on March 7, 2025, RBC Capital initiated coverage of GH Research (NasdaqGM:GHRS) with a Outperform recommendation. As of March 4, 2025, the average one-year price target for GH ...

Tuesday, GH Research PLC (NASDAQ:GHRS) received a reiterated Buy rating and $40.00 price target from H.C. Wainwright, representing significant upside potential for the $936... On Monday, Rodman ...